Methods and systems for treating cell proliferation related disorders

Patent metadata

Field	Value
Publication number	US-9682146-B2
Application number	US-201414450756-A
Country	US
Kind code	B2
Filing date	Aug 4, 2014
Priority date	Apr 8, 2007
Publication date	Jun 20, 2017
Grant date	Jun 20, 2017

Abstract

Methods for the treatment of a cell proliferation disorder in a subject, involving:
(1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.

First claim

The invention claimed is:

1. A method for treating cancer in a subject in need thereof, the method comprising:
administering to the subject a pharmaceutical agent comprising at least one of 8-methoxypsoralen (8-MOP) and 4′-aminomethyl-4,5′,8-trimethylpsoralen (AMT) that causes an auto-vaccine effect when activated;
administering to the subject at least one energy modulation agent comprising a phosphorescent, fluorescent, or luminescent agent that, upon reception of an initiation energy, emits light that activates the pharmaceutical agent; and
applying the initiation energy from an energy source to the subject, wherein the initiation energy is X-ray energy,
wherein the at least one energy modulation agent activates the pharmaceutical agent in situ with said light emitted from the phosphorescent, fluorescent, or luminescent agent, thus causing an auto-vaccine effect, wherein the auto-vaccine effect occurs in vivo in the subject in need, and wherein said auto-vaccine effect treats cancer, and
wherein the pharmaceutical agent is activated by one or more sequential single photon absorption events.

2. The method of claim 1 , wherein said auto-vaccine effect treats cancer by changing the cell proliferation rate of a cancer cell.

3. The method of claim 1 , wherein said at least one energy modulation agent is a single energy modulation agent, and is coupled to said pharmaceutical agent.

4. The method of claim 1 , wherein the pharmaceutical agent is contained within a photocage, wherein upon exposure to said X-ray energy, the photocage disassociates from the pharmaceutical agent, rendering the pharmaceutical agent available.

5. The method of claim 1 , wherein the pharmaceutical agent is coupled to a carrier that is capable of binding to a receptor site.

6. The method of claim 5 , wherein the carrier is one selected from insulin, interleukin, thymopoietin or transferrin.

7. The method of claim 5 , wherein the pharmaceutical agent is coupled to the carrier by a covalent bond.

8. The method of claim 5 , wherein the pharmaceutical agent is coupled to the carrier by a non-covalent bond.

9. The method of claim 5 , wherein the receptor site is one selected from nucleic acids of nucleated cells, antigenic sites on nucleated cells, or epitopes.

10. The method of claim 1 , wherein the pharmaceutical agent has affinity for a cancer cell.

11. The method of claim 1 , wherein pharmaceutical agent is capable of being preferentially absorbed by a cancer cell.

12. The method of claim 1 , wherein the pharmaceutical agent is contained within a photocage and is exposed to light emitted from the phosphorescent, fluorescent, or luminescent agent, wherein upon the exposure to light emitted from the phosphorescent, fluorescent, or luminescent agent, the photocage disassociates from the pharmaceutical agent, rendering the pharmaceutical agent available.

13. The method of claim 1 , wherein the at least one energy modulation agent and the pharmaceutical agent are independent and separately movable from each other.

Assignees

• Immunolight Llc
• Immunolight Llc

Inventors

• Bourke Jr Frederic A

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title